3850 – Anti-GP2 IgG

The Anti-GP2 IgG is a quantitative immunoassay for the determination of IgG antibodies against glycoprotein 2 (GP2) in human serum. The Anti-GP2 IgG is intended as an aid in the diagnosis of Crohn’s disease in conjunction with other clinical and laboratory findings.

Non-specific inflammatory bowel disease including Crohn’s disease (CD) (Enteritis regionalis) and ulcerative colitis (UC) are characterised by chronic-remitting inflammatory processes of the intestine. Immunologic, genetic, infectious and environmental factors have been identified as the risk factors of developing one of these diseases. Autoantibodies of exocrine pancreas (PAB) have been identified as specific serological marker for CD. Membrane-bound pancreatic Glycoprotein 2 (GP2) is the major target of PAB’s. PAB’s against GP2, in combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which is highly prevalent (70 %) in patients with CD and atypical antineutrophil cytoplasmatic antigens (aANCA), mainly found in patients with UC, could be used as a highly specific serological marker for differential diagnosis of CD to UC.

The ELISA (Enzyme Linked Immunosorbent Assay) is an immunoassay for the determination of specific antibodies. The strips of the microtiter plate are coated with test-specific antigens. If antibodies are present in the patient´s sample, they bind to the antigens. A secondary antibody conjugated with the enzyme peroxidase detects the generated immune complex. A colorless substrate is converted into the colored product. The signal intensity of the reaction product is proportional to the antibody activity in the sample. After stopping the signal intensity of the reaction product is measured photometrically.

The immunoassay is designed for manual professional in vitro diagnostic use.